<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of transformed accelerated phase chronic myeloid leukemia (AP CML)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of transformed accelerated phase chronic myeloid leukemia (AP CML)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Management of transformed accelerated phase chronic myeloid leukemia (AP CML)</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">This algorithm describes management of transformed AP CML (ie, AP CML that arose while the patient was receiving a TKI); importantly, management of transformed AP CML differs from that of de novo CML (ie, patients whose initial presentation is AP CML and who have not received prior TKI therapy).<br/>Refer to related UpToDate material for diagnostic criteria for transformed CML AP, selection of a TKI, and eligibility for allogeneic HCT.</div><div class="graphic_footnotes">CML: chronic myeloid leukemia; AP: accelerated phase; 2G TKI: second generation BCR-ABL1 tyrosine kinase inhibitor; HCT: hematopoietic cell transplantation.</div><div id="graphicVersion">Graphic 131961 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
